Macroangiopathy is a positive predictive factor for response to immunotherapy-Reference-Cited by-同舟云学术

Macroangiopathy is a positive predictive factor for response to immunotherapy

Published:2019-07-05 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Deike-Hofmann Katerina^ORCID,Gutzweiler Lukas,Reuter Julia,Paech Daniel^ORCID,Hassel Jessica C.,Sedlaczek Oliver,Radbruch Alexander,Schlemmer Heinz-Peter,Bäumer Philipp

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-46189-6.pdf

Reference46 articles.

1. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. & Rizvi, N. A. Nivolumab plus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 369, 122–33 (2013).

2. Hodi, F. S. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 363, 711–723 (2010).

3. Robert, C. et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

4. Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372, 2521–32 (2015).

5. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23–34 (2015).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Emerging Role and Clinical Applications of Morphomics in Diagnostic Imaging;Canadian Association of Radiologists Journal;2024-04-16

2. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy;Frontiers in Immunology;2023-11-22

3. Imaging-based adipose biomarkers for predicting clinical outcomes of cancer patients treated with immune checkpoint inhibitors: a systematic review;Frontiers in Oncology;2023-10-17

4. Contribution of skeletal muscle to cancer immunotherapy: A focus on muscle function, inflammation, and microbiota;Nutrition;2023-01

5. Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review;European Journal of Cancer;2022-11